Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/134516
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Combined BRAF, MEK, and CDK4/6 inhibition depletes intratumoral immune-potentiating myeloid populations in melanoma |
Author: | Lelliott, E.J. Mangiola, S. Ramsbottom, K.M. Zethoven, M. Lim, L. Lau, P.K.H. Oliver, A.J. Martelotto, L.G. Kirby, L. Martin, C. Patel, R.P. Slater, A. Cullinane, C. Papenfuss, A.T. Haynes, N.M. McArthur, G.A. Oliaro, J. Sheppard, K.E. |
Citation: | Cancer Immunology Research, 2021; 9(2):136-146 |
Publisher: | American Association for Cancer Research |
Issue Date: | 2021 |
ISSN: | 2326-6066 2326-6074 |
Statement of Responsibility: | Emily J. Lelliott, Stefano Mangiola, Kelly M. Ramsbottom, Magnus Zethoven, Lydia Lim, Peter K.H. Lau, Amanda J. Oliver, Luciano G. Martelotto, Laura Kirby, Claire Martin, Riyaben P. Patel, Alison Slater, Carleen Cullinane, Anthony T. Papenfuss, Nicole M. Haynes, Grant A. McArthur, Jane Oliaro, and Karen E. Sheppard |
Abstract: | Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring a BRAF(V600) mutation. While this triple therapy has potent tumor-intrinsic effects, the impact of this combination on antitumor immunity remains unexplored. Here, using a syngeneic Braf(V600E)Cdkn2a(−/−)Pten(−/−) melanoma model, we demonstrated that triple therapy promoted durable tumor control through tumor-intrinsic mechanisms and promoted immunogenic cell death and T-cell infiltration. Despite this, tumors treated with triple therapy were unresponsive to immune checkpoint blockade (ICB). Flow cytometric and single-cell RNA sequencing analyses of tumor-infiltrating immune populations revealed that triple therapy markedly depleted proinflammatory macrophages and cross-priming CD103⁺ dendritic cells, the absence of which correlated with poor overall survival and clinical responses to ICB in patients with melanoma. Indeed, immune populations isolated from tumors of mice treated with triple therapy failed to stimulate T-cell responses ex vivo. While combined BRAF, MEK, and CDK4/6 inhibition demonstrates favorable tumor-intrinsic activity, these data suggest that collateral effects on tumor-infiltrating myeloid populations may impact antitumor immunity. These findings have important implications for the design of combination strategies and clinical trials that incorporate BRAF, MEK, and CDK4/6 inhibition with immunotherapy for the treatment of patients with melanoma. |
Keywords: | Immunotherapy |
Rights: | ©2020 American Association for Cancer Research. |
DOI: | 10.1158/2326-6066.CIR-20-0401 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1100189 http://purl.org/au-research/grants/nhmrc/1139626 |
Published version: | http://dx.doi.org/10.1158/2326-6066.cir-20-0401 |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.